An International Publisher for Academic and Scientific Journals
Author Login 
SAS Journal of Medicine | Volume-12 | Issue-10
Cost and Morbidity of Three-Dimensional Laparoscopic Living Donor Nephrectomy in Morocco
Y. K. Echchamchi, T. Jalil, A. Chatar, M. A. Lakmichi, Z. Dahami, I. Sarf, M. Chettati, W. Fadili, I. Laouad
Published: Oct. 12, 2026 | 23 15
Pages: 1078-1083
Downloads
Abstract
Objective. To describe hospital tariff-based direct medical expenditure and morbidity associated with three-dimensional laparoscopic living donor nephrectomy at a Moroccan university hospital. Methods. This retrospective descriptive single centre study included 51 donors operated on between January 2014 and December 2023. All procedures were left transperitoneal laparoscopic nephrectomies using 3D vision. Expenditure was valued using the national professional fee schedule and hospital administrative data. Morbidity was reported using the Clavien–Dindo classification. An exploratory scenario replaced the five hospital days used in the costing schedule with the reported mean length of stay. Results. Mean donor age was 49.12 years; 33 donors were women and 18 were men. Mean total and postoperative stays were 6.87 and 3.62 days, respectively. Estimated tariff-based expenditure was 17,714.75 Moroccan dirhams (MAD) per procedure. Dedicated laparoscopic equipment accounted for 10,050 MAD (56.7%). Substituting 6.87 hospital days increased the estimate to 18,088.75 MAD (+2.1%). Reported Clavien–Dindo grade I and II complication rates were 35.29% and 7.84%, respectively, while 56.86% of donors had no complication. No conversion, transfusion, reoperation or intensive care admission was reported. One incisional hernia and two glomerular filtration rate values below 60 mL/min were reported without documented timing. Conclusion. This series describes 3D laparoscopic donor nephrectomy in a Moroccan university setting, with dedicated equipment accounting for most tariff-based expenditure. The absence of a comparator, full costing and standardized follow-up precludes conclusions about the incremental economic value of 3D vision or long-term donor safety.